FDA Cracks Down on Compounded GLP-1 Weight Loss Drugs
FDA plans to restrict non-approved compounded GLP-1 drugs sold by Hims & Hers and compounding pharmacies, citing safety concerns and misleading marketing practices.
FDA plans to restrict non-approved compounded GLP-1 drugs sold by Hims & Hers and compounding pharmacies, citing safety concerns and misleading marketing practices.
Hims is selling a $49 copycat of Novo Nordisk's $149 weight-loss pill, but legal experts say Novo may avoid court battles due to risks of setting dangerous precedents.
FDA takes aim at compounded weight-loss drugs like Hims' $49 Wegovy alternative, raising safety concerns over unapproved copycat medications flooding the market.
Hims & Hers offers compounded semaglutide pill at $49/month introductory price, significantly undercutting Novo Nordisk's $199 Wegovy brand-name treatment with same active ingredient.
Hims & Hers partners with Grail to offer discounted Galleri cancer detection tests through its Labs subscription service, expanding beyond weight-loss treatments.
Amazon Pharmacy now sells Wegovy weight-loss pill. Insured pay $25/month, uninsured start at $149. Needle-free option available nationwide.